Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Mps-BAY2b + Paclitaxel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Mps-BAY2b||MPS1 Inhibitor 25||Mps-BAY2b, is an imidazopyrazine that inhibits TTK (MPS1) to derail the spindle assembly checkpoint and induce cell cycle arrest (PMID: 23933817).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colon carcinoma||not applicable||Mps-BAY2b + Paclitaxel||Preclinical||Actionable||In a preclinical study, Mps-BAY2b, in combination with paclitaxel, had increased efficacy in inhibiting cell proliferation of colon carcinoma cell in culture (PMID: 23933817).||23933817|
|Unknown unknown||cervical cancer||not applicable||Mps-BAY2b + Paclitaxel||Preclinical||Actionable||In a preclinical study, Mps-BAY2b, in combination with paclitaxel, had increased efficacy in decreasing tumor volume of cervical carcinoma xenografts (PMID: 23933817).||23933817|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|